Ontology highlight
ABSTRACT:
SUBMITTER: Belch A
PROVIDER: S-EPMC7724300 | biostudies-literature | 2020 Dec
REPOSITORIES: biostudies-literature
Belch Andrew A Bahlis Nizar N White Darrell D Cheung Matthew M Chen Christine C Shustik Chaim C Song Kevin K Tosikyan Axel A Dispenzieri Angela A Anderson Kenneth K Brown Diane D Robinson Suzanne S Srinivasan Shankar S Facon Thierry T
Cancer medicine 20201013 23
The phase 3 FIRST trial demonstrated significant improvement in progression-free survival (PFS) and overall survival (OS) with an immune-stimulatory agent, lenalidomide, in combination with low-dose dexamethasone until disease progression (Rd continuous) vs melphalan +prednisone + thalidomide (MPT) in transplant-ineligible patients with newly diagnosed multiple myeloma (NDMM). Rd continuous similarly extended PFS vs fixed-duration Rd for 18 cycles (Rd18). Outcomes in the Canadian/US subgroup (10 ...[more]